Clinical Research Directory
Browse clinical research sites, groups, and studies.
Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies
Sponsor: University Hospital, Grenoble
Summary
Pseudomonas aeruginosa is a pathogenic bacteria for human, especially in hospital settings. It can sometimes be multi-resistant to many or even to all antibiotics usually used for its treatment. The aim of the study is to isolate and produce therapeutic antibodies against the bacteria Pseudomonas aeruginosa in order to provide an alternative treatment to antibiotics in case of infection with an antibiotic-resistant strain of Pseudomonas aeruginosa.
Official title: Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies From B Lymphocytes of Patients Who Have Been Followed for Infection or Colonization With Pseudomonas Aeruginosa: a Prospective Monocentric Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
30
Start Date
2020-10-05
Completion Date
2026-10
Last Updated
2025-11-20
Healthy Volunteers
No
Interventions
Isolation of anti-Pseudomonas antibodies from type B lymphocytes
Blood sampling. Isolation of mononuclear cells from human peripheral blood by density gradient centrifugation. Identification of functional anti-Pseudomonas antibodies by ELISA and cellular infection assays.
Locations (1)
Chu Grenoble Alpes
Grenoble, France